PMID: 21849531
Question: Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency?
Correct Answer: no

======================= Launch the MCC process =======================
PMID: 21849531
Question: Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content:** The question investigates whether growth hormone (GH) replacement therapy can reduce mortality rates in adults diagnosed with growth hormone deficiency (GHD).
- **Key Information to Identify:** 
  - Comparative mortality rates between treated and untreated groups.
  - Specific mortality causes affected by GH therapy (e.g., cardiovascular disease, malignancies).
  - Differences in outcomes based on patient characteristics such as gender.
  
**2. Evidence Evaluation**
- **Research Results:**
  - In the treatment group, the standardized mortality ratio (SMR) was 1.27, indicating a higher mortality rate compared to the expected background population.
  - Specifically, mortality remained elevated for cardiovascular diseases in women even after excluding high-risk patients.
  - Mortality due to malignancies was not increased in the GH-treated group.
  - Control groups (primary and secondary) did not show a difference in mortality compared to the background population.
- **Strength and Reliability:**
  - The study is a nationwide cohort study with a substantial sample size (n=2229 treatment group).
  - Retrospective monitoring over a long period (1985-2009) enhances the reliability of the findings.
- **Relevance to the Question:**
  - The evidence directly addresses the impact of GH therapy on all-cause and cause-specific mortality in adults with GHD.
  - Gender-specific outcomes provide a nuanced understanding of the therapy's effects.

**3. Conclusion**
Based on the evidence, GH replacement therapy does not reduce overall mortality in adults with GHD and may be associated with increased cardiovascular mortality in women. Therefore, the therapy does not support a reduction in mortality rates universally across the adult GHD population.

**4. Final Answer**
**My final choice is: "no"**
GPT selected: no

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether growth hormone (GH) replacement therapy reduces all-cause mortality in adults with GH deficiency. Key points to assess:  
- The study's comparison of mortality rates between treated and untreated groups.  
- Standardized mortality ratios (SMRs) and cause-specific mortality (e.g., cardiovascular disease, malignancies).  
- Subgroup analyses (e.g., sex, risk factors).  

**2. Evidence Evaluation**  
- **Treatment Group**: The SMR for all-cause mortality was 1.27 (95% CI 1.04–1.56), indicating a 27% higher mortality than the general population.  
- **Subgroup Analysis**:  
  - **Men**: Mortality was comparable to the background population (SMR ≈ 1).  
  - **Women**: After excluding high-risk patients, mortality remained elevated for cardiovascular disease (CVD) but not malignancies.  
- **Control Groups**: Untreated or partially treated groups showed mortality similar to the background population.  
- **Limitations**: The study is observational (retrospective cohort), and confounding factors (e.g., baseline risks, heterogeneous etiologies) may influence results.  

**3. Conclusion**  
The study found that GH-treated adults overall had increased mortality compared to the general population (SMR >1). However, subgroup analyses showed that men on GH had mortality similar to the background population, while women had elevated CVD-related mortality. Since the question asks about mortality reduction in **all adults** with GHD, the overall increased SMR suggests GH therapy does not reduce mortality.  

**4. Final Answer:**  
**My final choice is: "no"**
Qwen selected: no

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether GH replacement therapy reduces mortality in adults with GHD. Key points to evaluate include:  
- Mortality rates (all-cause, CVD, malignancy) in treated vs. untreated groups.  
- Standardized mortality ratios (SMR) compared to the general population.  
- Gender-specific outcomes and confounding factors (e.g., underlying diagnosis).  

**2. Evidence Evaluation**  
- **Treated group**: All-cause SMR was 1.27 (95% CI: 1.04–1.56), indicating **higher mortality** than the general population.  
- **Gender differences**:  
  - **Men**: Mortality in GH-treated men matched the background population.  
  - **Women**: After excluding high-risk patients, CVD mortality remained elevated.  
- **Control groups (untreated)**: Mortality was similar to the background population.  
- **Malignancy**: No elevated risk in treated patients.  
- **Confounding factors**: Sex, GHD onset, age, and underlying diagnosis influenced outcomes.  

**3. Conclusion**  
The study shows **no overall mortality reduction** with GH therapy:  
- Treated patients had **higher all-cause mortality** than the general population.  
- Untreated controls showed **no excess mortality**, suggesting GH therapy does not confer a survival advantage.  
- Gender-specific results (men’s mortality normalizing, women’s CVD risk persisting) and confounding etiologies complicate generalizability.  

**4. Final Answer**  
**My final choice is: "no"**
DeepSeek selected: no

Initial consensus: All models selected no

